Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma

摘要: An esophagectomy with three-field lymph node dissection is the standard therapy for esophageal cancer in many countries, including Japan. However, results of are still unsatisfactory comparison to surgical treatment gastric or colon cancer. On other hand, definitive chemoradiation has recently shown progress as a modality resectable cancer, data indicating potential efficacy combination and an esophagectomy. In fact, preoperative chemoradiotherapy becoming Europe North America. The latest metaanalysis concerning neoadjuvant concluded that significant survival benefit was evident chemoradiotherapy. there no supportive surgery from well-designed large-scale randomized control trial (RCT). A RCT needed determine utility chemoradiation. Future trials based on precise diagnosis procedures required adequate interpretation Of course, quality operation very important factor, because operative mortality influences these results.